[ad_1]
The coronavirus is one of humanity’s greatest challenges in recent times. People lose their lives every day in the coroner’s throat.
The researchers claim that this has made Corona the most effective weapon to control. Researchers discover new drugs to protect against crowns. Now being developed in Bangladesh.
Fujifilm Toyama Pharmaceuticals Ltd. of Japan Faviperavir developed the tablet called ‘Avigan’. It is possible to kill the coronavirus effectively.
Recently, at least a dozen drugs such as favipiravir, remdecivir, interferon alfa tubi, ribavirin, chloronquinine, lopinavir, and arbidol covid-1 have been sent to the treatment line. Although not directly manufactured for the new coronavirus, drugs used against other viruses have been used experimentally to prevent the coronavirus.
Tablet Avigan, a subsidiary of Japan Fuji Film Company’s Toyoma Chemical pharmaceutical company, for the treatment of coronavirus. The generic name of the tablet is Flavipiravir. The drug is now beginning to be manufactured by Beximco and Beacon Pharmaceuticals in Bangladesh.
Beacon Pharmaceuticals will deliver the medication next Sunday to the Department of Health and the Administration of Medications. In addition to supplying the drug to the government, it will also be provided in hospitals where there are coronary patients. But it will not be provided at the pharmacy at this time.
Due to a shortage of material, the drug will now be manufactured for just 1 patient, but the company will increase production within this month, the company said.
Beximco Pharmaceuticals will deliver the medicine to the hospital where the coronary patient is admitted. Each tablet costs Rs.5, but will now be provided free of charge to patients.
Although Japan has a patent to manufacture the medicine, as a developed country, they have allowed Bangladesh to manufacture the medicine for up to 20 years.
Flavivirvir is not a definitive treatment for Koviv-1 disease, but it has been successful in examining 120 patients. Covid-1 has been negative for seven days using the drug in young patients and nine days after using it in the elderly.
The trials have been carried out in conjunction with Flavipiravine, another medicine called Oravesco.
Japan, Turkey and China are using the drug. There are three stages of the disease: common, moderate, and severe. In all three cases, the medication is effective. The medicine has side effects in the unborn baby.
So far, no drug has been found to be effective in suppressing the virus. No vaccine or vaccine was discovered. However, at least a dozen drugs, such as favivirivir, remdecivir, interferon alfa tubi, ribavirin, chloronquinine, lopinavir, and Arabidol, have been sent to the Covid-I treatment line. Although not directly manufactured for the new coronavirus, experimental medications have been used to prevent Covid-1, a medication that works against other viruses.
In a research paper led by Professor Jinghuang Wang of Wuhan University, China, published in a preprinted journal titled ‘Medical Archive,’ published April 4, Avignon fever, cough, and respiratory treatment in a comparative clinical trial. with Arabidopsis. It can be used
Their research says that for the Avignon Clinical Trial, from February 25 to March 12, the Jungan Hospital of Wuhan University of China, the Wuhan Leshan Hospital and another hospital in Hubei province, at least 3 percent of patients suffering from at least 7 percent of seven CW-3 fever, cough, and cough in seven days were. Apart from these, there was no need to provide artificial oxygen for the breathing of these patients.
Most of the Covid-I patients had diabetes, kidney problems, high blood pressure and respiratory problems. These researchers claim that Avignon has worked well in the bodies of these patients.
One of the antiviral drugs is Favipiravir Avigon manufactured by Fujifilm Toyama Pharmaceuticals Ltd. of Japan. It has been manufactured for the treatment of influenza for over 20 years. The Chinese government said last March that it had done a good job of preventing ‘Covid-1’ after China suffered mass deaths. A month after the Chinese lawsuit, Japan’s Minister of Health, Labor and Welfare Katsunobu Kato indicated that “Avignon” is planning to test against Covid-1.
And then Japan basically started preparing Avignon for Quid-1. In a statement released on March 5, Fujifilm president Junizi Okada claimed that Avignon, a generic drug in Favipiravir, had begun a Phase III clinical trial. They said they would supply the drug in consultation with the Japanese government based on demand from other countries around the world to prevent the Covid-I epidemic.
The United States Food and Drug Administration has not yet approved any medications for the treatment of Koviv-1. Flavipiravir has not yet been approved by the World Health Organization, the UK Department of National Health, and the Australian Department of Health. The trial in Italy has given good results but has not yet been officially approved. The drug is currently undergoing testing in 25 countries. If Avignon can really prevent the coronavirus, it will be the greatest achievement of this century.
(DhakaTimes / April 1 / RZ / AZ)
[ad_2]
